An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants

NCT01290679 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

393

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: Placebo
DRUG: TMC435
DRUG: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)
DRUG: Ribavirin (RBV)

Sponsor

Janssen R&D Ireland